| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -7,953 | -5,683 |
| Purchase of property and equipment | 2 | 2 |
| Net cash used in investing activities | -2 | -2 |
| Gross proceeds from equity financing | 12,102 | - |
| Issuance costs from equity financing | 1,299 | - |
| Proceeds from exercise of common warrants | 25 | 25 |
| Proceeds from exercise of stock options | 17 | 17 |
| Proceeds from equity financing, net of issuance cost | - | 10,803 |
| Net cash provided by financing activities | 10,845 | 10,845 |
| Net increase in cash and cash equivalents | 2,890 | 5,160 |
| Cash and cash equivalents at beginning of period | 7,154 | - |
| Cash and cash equivalents at end of period | 10,044 | - |
RenovoRx, Inc. (RNXT)
RenovoRx, Inc. (RNXT)